Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Sponsor: Zensun Sci. & Tech. Co., Ltd.
A PHASE3 clinical study on Chronic Heart Failure, this trial is terminated or withdrawn. The trial is conducted by Zensun Sci. & Tech. Co., Ltd. and has accumulated 7 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Jan 2018 [monthly]
Terminated PHASE3
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Zensun Sci. & Tech. Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China, Changchun, China, Changsha, China, Chengdu, China, Chongqin, China, Dalian, China, Daqing, China, Haerbin, China, Haikou, China, Hangzhou, China and 18 more location s